ROCKVILLE, Md.--(BUSINESS WIRE)--BioFactura, Inc., announced that the first test kits for viral hemorrhagic fever diagnosis have completed initial clinical testing in West Africa. The clinical test kits were developed under a $3.8M grant awarded by the National Institutes of Health (NIH) and were developed by BioFactura in collaboration with Tulane University, the US Army Medical Research Institute of Infectious Diseases (USAMRIID), Corgenix Medical Corp, Autoimmune Technologies, and partners in West Africa.
